Cargando…

Classic Psychedelic Drugs: Update on Biological Mechanisms

Renewed interest in the effects of psychedelics in the treatment of psychiatric disorders warrants a better understanding of the neurobiological mechanisms underlying the effects of these substances. During the past two decades, state-of-the-art studies of animals and humans have yielded new importa...

Descripción completa

Detalles Bibliográficos
Autores principales: Vollenweider, Franz X., Smallridge, John W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110100/
https://www.ncbi.nlm.nih.gov/pubmed/35079988
http://dx.doi.org/10.1055/a-1721-2914
_version_ 1784709026461777920
author Vollenweider, Franz X.
Smallridge, John W.
author_facet Vollenweider, Franz X.
Smallridge, John W.
author_sort Vollenweider, Franz X.
collection PubMed
description Renewed interest in the effects of psychedelics in the treatment of psychiatric disorders warrants a better understanding of the neurobiological mechanisms underlying the effects of these substances. During the past two decades, state-of-the-art studies of animals and humans have yielded new important insights into the molecular, cellular, and systems-level actions of psychedelic drugs. These efforts have revealed that psychedelics affect primarily serotonergic receptor subtypes located in cortico-thalamic and cortico-cortical feedback circuits of information processing. Psychedelic drugs modulate excitatory-inhibitory balance in these circuits and can participate in neuroplasticity within brain structures critical for the integration of information relevant to sensation, cognition, emotions, and the narrative of self. Neuroimaging studies showed that characteristic dimensions of the psychedelic experience obtained through subjective questionnaires as well as alterations in self-referential processing and emotion regulation obtained through neuropsychological tasks are associated with distinct changes in brain activity and connectivity patterns at multiple-system levels. These recent results suggest that changes in self-experience, emotional processing, and social cognition may contribute to the potential therapeutic effects of psychedelics.
format Online
Article
Text
id pubmed-9110100
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-91101002022-05-17 Classic Psychedelic Drugs: Update on Biological Mechanisms Vollenweider, Franz X. Smallridge, John W. Pharmacopsychiatry Renewed interest in the effects of psychedelics in the treatment of psychiatric disorders warrants a better understanding of the neurobiological mechanisms underlying the effects of these substances. During the past two decades, state-of-the-art studies of animals and humans have yielded new important insights into the molecular, cellular, and systems-level actions of psychedelic drugs. These efforts have revealed that psychedelics affect primarily serotonergic receptor subtypes located in cortico-thalamic and cortico-cortical feedback circuits of information processing. Psychedelic drugs modulate excitatory-inhibitory balance in these circuits and can participate in neuroplasticity within brain structures critical for the integration of information relevant to sensation, cognition, emotions, and the narrative of self. Neuroimaging studies showed that characteristic dimensions of the psychedelic experience obtained through subjective questionnaires as well as alterations in self-referential processing and emotion regulation obtained through neuropsychological tasks are associated with distinct changes in brain activity and connectivity patterns at multiple-system levels. These recent results suggest that changes in self-experience, emotional processing, and social cognition may contribute to the potential therapeutic effects of psychedelics. Georg Thieme Verlag KG 2022-01-25 /pmc/articles/PMC9110100/ /pubmed/35079988 http://dx.doi.org/10.1055/a-1721-2914 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Vollenweider, Franz X.
Smallridge, John W.
Classic Psychedelic Drugs: Update on Biological Mechanisms
title Classic Psychedelic Drugs: Update on Biological Mechanisms
title_full Classic Psychedelic Drugs: Update on Biological Mechanisms
title_fullStr Classic Psychedelic Drugs: Update on Biological Mechanisms
title_full_unstemmed Classic Psychedelic Drugs: Update on Biological Mechanisms
title_short Classic Psychedelic Drugs: Update on Biological Mechanisms
title_sort classic psychedelic drugs: update on biological mechanisms
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110100/
https://www.ncbi.nlm.nih.gov/pubmed/35079988
http://dx.doi.org/10.1055/a-1721-2914
work_keys_str_mv AT vollenweiderfranzx classicpsychedelicdrugsupdateonbiologicalmechanisms
AT smallridgejohnw classicpsychedelicdrugsupdateonbiologicalmechanisms